Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?

Patricia Martin-Romano; Julien Adam; Jean-Yves Scoazec; Sébastien Gouy; Antonin Levy; Capucine Baldini; Stéphane Champiat; Jean-Charles Soria; Jean-Charles Soria; Jean-Charles Soria; Christophe Massard; Aurélien Marabelle; Eric Deutsch; Eric Deutsch; Eric Deutsch; Antoine Hollebecque

doi:10.3389/fimmu.2021.745146

Frontiers in Immunology (Nov 2021)

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?

Patricia Martin-Romano,
Julien Adam,
Jean-Yves Scoazec,
Sébastien Gouy,
Antonin Levy,
Capucine Baldini,
Stéphane Champiat,
Jean-Charles Soria,
Jean-Charles Soria,
Jean-Charles Soria,
Christophe Massard,
Aurélien Marabelle,
Eric Deutsch,
Eric Deutsch,
Eric Deutsch,
Antoine Hollebecque

Affiliations

Patricia Martin-Romano: Early Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France
Julien Adam: Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France
Jean-Yves Scoazec: Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France
Sébastien Gouy: Department of Surgery, Gustave Roussy Cancer Campus, Villejuif, France
Antonin Levy: Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Capucine Baldini: Early Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France
Stéphane Champiat: Early Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France
Jean-Charles Soria: Early Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France
Jean-Charles Soria: Institut National de la Santé et de la Recherche Médicale (INSERM), Gustave Roussy Cancer Campus, Villejuif, France
Jean-Charles Soria: Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
Christophe Massard: Early Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France
Aurélien Marabelle: Early Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France
Eric Deutsch: Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Eric Deutsch: Institut National de la Santé et de la Recherche Médicale (INSERM), Gustave Roussy Cancer Campus, Villejuif, France
Eric Deutsch: Université Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
Antoine Hollebecque: Early Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France

DOI: https://doi.org/10.3389/fimmu.2021.745146
Journal volume & issue: Vol. 12

Abstract

Read online

Immunotherapy has dramatically changed the treatment landscape for several tumor types. However, the impact of previous radiotherapy (RT) on response to immunotherapy is still unknown. We report the case of a 58-year-old female diagnosed with a squamous anal cell carcinoma previously treated with RT and having a dissociated response to anti-PD1 agent. An extensive analysis of the immune contexture performed on the tissue collected from both previously RT-treated and RT-untreated lesions confirmed differences on immune microenvironment, highlighting the potential impact of radiotherapy on the immune response.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords